92246-88-3Relevant academic research and scientific papers
ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES
-
, (2022/01/04)
The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications
BORONIC ESTER AND ACID COMPOUNDS
-
, (2008/06/13)
Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
Angiotensin II antagonists
-
, (2008/06/13)
This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
Angiotensin II antagonist intermediates
-
, (2008/06/13)
This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
Angiotensin II antagonists
-
, (2008/06/13)
This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.
Alkyl substituted nitroimidazole acetic acids
-
, (2008/06/13)
This invention provides the substantially pure (R) enantiomer of a compound of the Formula II: STR1 The compounds of Formula II are useful in the preparation of the substantially pure (R) enantiomer of angiotensin II antagonists of Formula III: STR2 where
